| Literature DB >> 27930662 |
Ahmed M Abou-Setta1,2, Maya Jeyaraman1, Abdelhamid Attia3, Hesham G Al-Inany3, Mauricio Ferri4, Mohammed T Ansari5, Chantelle M Garritty5, Kenneth Bond6, Susan L Norris4.
Abstract
INTRODUCTION: Rapid reviews (RR), using abbreviated systematic review (SR) methods, are becoming more popular among decision-makers. This World Health Organization commissioned study sought to summarize RR methods, identify differences, and highlight potential biases between RR and SR.Entities:
Mesh:
Year: 2016 PMID: 27930662 PMCID: PMC5145149 DOI: 10.1371/journal.pone.0165903
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Geographic distribution of organizations conducting rapid evidence synthesis with methods available for review.
| Country | Number of organizations |
|---|---|
| Australia | 3 |
| Austria | 1 |
| Canada | 12 |
| Finland | 1 |
| Germany | 1 |
| Italy | 1 |
| Sweden | 1 |
| Taiwan | 1 |
| UK | 4 |
| USA | 4 |
Summary of methods used by organizations in conducting rapid evidence synthesis.
| Rapid review definition: | Variable; usually carries two important concepts: “need to be timely/ efficient” and “use of limited systematic review methodology”. Often these two observations are coupled to express a trade-off between being “rapid” and being “comprehensive”. |
| Average time to complete (months): | Mean (SD): 3.2 months (2.3 months); Median (IQR): 3.0 months (1.8 to 4.0 months); Range: 0.5 to 12 months. |
| Official intake/ review process: | Most organizations (81%) have an official intake/ review process for prospective requests for rapid reviews. The reviewers may provide possible tweaks on the original question, but cannot usually propose an alternate topic. Some groups ranked requests for importance to assist in the intake process. |
| Type(s) of research question(s) rapidly reviewed: | Variable; ranged widely, based on organizational needs, but includes clinical efficacy, effectiveness, safety, and cost-effectiveness. |
| Main focus of the final review report: | Inform/ support patients, clinicians and decision-makers in some capacity (100% of organizations). |
| A priori protocol: | Protocols commonly prepared (84%), but rarely registered (n = 4; 16%). |
| Databases regularly searched: | Most searched at least 3 bibliographic databases, but numbers varied markedly. Most identified “PubMed/ Medline”, “Cochrane Library” and “EMBASE” as the most frequently searched. |
| Identifying previous systematic reviews and primary studies: | Previous systematic reviews were frequently searched (100%) along with recent primary studies (78%). Some groups only search for systematic reviews, while others search for primary studies if no systematic reviews are identified. |
| Search limits: | Most common limits were for publication year (63%), language (72%) and study design. |
| Grey literature searching: | Grey literature is variably searched (56%). |
| Peer-reviewing search strategies: | If conducted, usually performed internally within the organization (38%). |
| Number of reviewers selecting studies: | Variable; different groups used only a single reviewer (41%), one reviewer checks the decisions made by another reviewer (9%), two independent reviewers (38%), or one to two reviewers (project-specific). |
| Number of data extractors: | Variable; different groups used only a single reviewer (41%), one reviewer checks the decisions made by another reviewer (25%), two independent reviewers (22%), or one to two reviewers (project-specific). |
| Data extracted from included studies: | Study characteristics, population demographics, intervention/ comparator characteristics, and outcome measures (numerical and categorical data) usually extracted. Outcomes measures often limited by scope of review, or set a priori. |
| Summary evidence presentation: | Narrative summary (most frequent; 91%), but may include vote-counting and/ or meta-analysis (less frequently; 6%). |
| Critical appraisal of the internal validity of the included studies: | Variable: different groups used only a single reviewer, one reviewer checks the decisions made by another reviewer, two independent reviewers, or one to two reviewers (project-specific). Some groups do not conduct critical appraisal. No consensus on which tool(s) to use. |
| Study author/ industry contact for missing data, unpublished trials, or feedback: | Infrequently performed by any organization (25%). |
| Items presented in final review report: | Variable: usually contains “recommendations”, “implications for policy”, and “an explanation of the strengths/ weakness of the review methods used (e.g. disclaimer)”. |
| Peer-review: | Some sort of peer-review usually conducted (94%), but often limited to internal review and feedback from requestor; variable external peer-review. |
| Final report dissemination: | Final report frequently disseminated to individuals other than the requestor (88%). |
| KT/ dissemination tools: | Variable: organization-specific, but conclusions of most rapid reviews are posted online in some form (e.g. organizational website, social media) (72%). |
Summary of studies comparing systematic reviews and rapid.
| Study | Methods | Results |
|---|---|---|
| Comparison of 21 rapid reviews conducted by SMC vs. systematic review by NICE. | Methods used by SMC and NICE are markedly different. Even so, main conclusions (accept/ reject new medicines or technology) were similar in most reviewed cases (20/ 21). | |
| Comparison of seven rapid vs. four systematic reviews conducted independently by different groups. | Methodology of rapidly reviewing the evidence differed between rapid reviews reviewed, and often under-reported. Scope is narrower for rapid reviews, but main conclusions often don’t differ. | |
| Comparison of one rapid review conducted by Canadian Agency for Drugs and Technologies in Health vs. systematic review conducted by Technology Assessment Unit (McGill University). | Methods used by the rapid review and the full review differed in several aspects. Even so, the conclusions of both reviews were similar. | |
| Comparison of two rapid NICE STAs vs. one full systematic TAR for the same healthcare technologies. | Methods used by STAs require more dependence on data submitted by industry with limited capacity for additional searching for data. Conclusions were similar, but sources of evidence were variably absent in the STA assessments. | |
| Comparison of one journal-published rapid review vs. one journal-published systematic review. | Methods used by rapid review were abbreviated as compared with the systematic review. This led to identifying only a fraction of the available trials found by the full review (3/ 44). Even so, main conclusions were not different, but differences were evident in identified associations and confounding factors. | |
| Comparison of rapid review conducted by IQWiG and systematic reviews. | Methods were inconsistent across systematic reviews and showed some similarities/ differences with the IQWiG rapid review. Trial identification was not only different due to differences in search criteria and sources of evidence, but also study included study designs. | |
| Comparison of rapid vs. exhaustive health technology assessments. | Both types of HTA reports offer similar information for decision-makers, especially when presenting cost-effectiveness analysis, ethical and legal impacts, or exploring critical uncertainties and proposals for clarifying them. | |
| Comparison of one journal-published rapid review vs. one journal-published systematic review. | Methods used by rapid review were abbreviated as compared with the systematic review. Even so, both reviews identified different trials with only 15% of trials included by both reviews; leading to conflicting conclusions by the two reviews. | |
| Comparison of 39 interventional procedures evaluated by the British United Provident Association`s rapid appraisal algorithm vs. full National Institute for Health and Clinical Excellence health technology assessment. | Both rapid and full evaluations resulted in similar conclusions (90% of evaluations). |
IQWiG = Institute for Quality and Efficiency in Health Care; NICE = National Institutes of Clinical Evidence; SMC = Scottish Medicines Consortium; STA = Single Technology Assessments; TAR = Technology Assessment Report